Researchers from the University of Aarhus in Denmark investigated the concentrations of adalimumab and infliximab in the umbilical cord blood of 80 newborn infants born in hospitals in Denmark, Australia and New Zealand between March 2012 and November 2014. Of the 80 women, 36 received adalimumab and 44 received infliximab. The researchers also investigated the rates of clearance after birth born to mothers with IBD.
Here are five points:
1. Adalimumab took an average of four months to clear the infants’ bodies.
2. Infliximab took an average of 7.33 months to clear the infants’ bodies.
3. Antibodies for anti tumor necrosis factors remained in infants until they reached 12 months of age.
4. The relative risk for infection in infants whose mothers received the combination of an anti TNF agent and thiopurine was 2.7.
5. The researchers recommend the anti TNF mothers’ infants should not receive a live virus vaccine during their first year of life.
More articles on GI & endoscopy:
PENTAX Medical launches OPTIVISTA video processor in the US, Medigus’ MUSE system safe for long-term GERD treatment & more — 14 GI company key notes
GI physicians, PCPs have differing reasons for recommending surveillance colonoscopy to seniors: 5 findings
Approximately 50% of Crohn’s disease patients receiving STELARA achieved clinical remission: 4 insights from a new study
